Therapeutic targeting of a gene to inhibit tumour angiogenesis, and consequently, the tumour growth, usually involves silencing of the genes by siRNA or the use of specific neutralizing antibodies to angiogenic molecules like VEGF, angiopoietin etc. NRP-1 expression by the tumour cells has been known to promote tumour angiogenesis and progression [61], [53] and an exogenous expression of NRP-1 has been shown to be sufficient to drive angiogenesis [53]. The gene discussed is VEGFA; the disease is neoplasm.